Internal link ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares October 18, 2019 at 12:20 PM UTC
Internal link ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares October 16, 2019 at 03:17 AM UTC
Internal link ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares October 15, 2019 at 09:15 PM UTC
Internal link ProQR Receives Rare Pediatric Disease Designation from FDA for Sepofarsen for the Treatment of LCA10 October 15, 2019 at 08:08 PM UTC
Internal link ProQR annonce des premiers résultats positifs pour l'essai de phase 1/2 du sepofarsen chez des patients souffrant d'ACL10 October 11, 2019 at 10:02 AM UTC
Internal link ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients October 10, 2019 at 10:00 AM UTC
Internal link ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO October 07, 2019 at 11:00 AM UTC
Internal link ProQR to Present at Two Investor Conferences in October September 30, 2019 at 11:00 AM UTC
Internal link ProQR Receives Fast Track Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa September 09, 2019 at 11:00 AM UTC
Internal link ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP) August 12, 2019 at 11:00 AM UTC
Internal link ProQR Announces Financial Results for the Second Quarter of 2019 August 07, 2019 at 11:00 AM UTC
Internal link L’Agence européenne des médicaments accorde l’accès PRIME au Sepofarsen de ProQR pour l’amaurose congénitale de Leber 10 July 29, 2019 at 04:37 PM UTC
Internal link European Medicines Agency Grants PRIME Access to ProQR’s Sepofarsen for Leber’s Congenital Amaurosis 10 July 29, 2019 at 11:00 AM UTC
Internal link ProQR Announces Presentation on QR-421a Program in Ophthalmology at Usher Syndrome Coalition Conference in July July 02, 2019 at 11:00 AM UTC
Internal link ProQR to Present at the JMP Securities Life Sciences Conference June 03, 2019 at 11:00 AM UTC
Internal link ProQR to Present at the RBC Capital Markets Healthcare Conference May 15, 2019 at 11:00 AM UTC
Internal link ProQR Announces Financial Results for the First Quarter of 2019 May 08, 2019 at 11:00 AM UTC
Internal link ProQR to Present at Three Scientific Conferences in April April 22, 2019 at 11:00 AM UTC
Internal link ProQR nominates Bart Filius, COO and CFO at Galapagos and Theresa Heggie, Head of CEMEA at Alnylam for its Supervisory Board April 18, 2019 at 11:00 AM UTC
Internal link ProQR Doses First Patient in Phase 2/3 ILLUMINATE Trial of Sepofarsen for LCA10 April 15, 2019 at 11:00 AM UTC
Internal link ProQR to Present at the H.C. Wainwright Global Life Sciences Conference April 01, 2019 at 11:00 AM UTC
Internal link ProQR spins out all Dystrophic Epidermolysis Bullosa activities into newly formed Wings Therapeutics created by EB Research Partnership March 26, 2019 at 08:01 PM UTC
Internal link ProQR traite le premier patient dans l’essai STELLAR de Phase 1/2 du QR-421a pour le syndrome d’Usher de type 2 March 11, 2019 at 04:45 PM UTC
Internal link ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2 March 11, 2019 at 12:00 PM UTC